Home >> Alzheimer's Disease >> Alzheimer's Disease >> Wine >> Technology & Media >>

Rosacea - Pipeline Review, H1 2013

Published: Mar-2013 | Format: PDF | Global Markets Direct | Number of pages: 67 | Code: MRS - 978

Global Markets Directs, 'Rosacea Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea. 

Rosacea Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Rosacea.
A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry -specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Rosacea pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Rosacea.
Identify emerging players with potentially strong product portfolio and design effective counter -strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics.
Develop and design in -licensing and out -licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rosacea Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Rosacea 8
Rosacea Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre -Clinical Stage Products 15
Comparative Analysis 15
Rosacea Therapeutics - Products under Development by Companies 16
Companies Involved in Rosacea Therapeutics Development 17
Allergan, Inc. 17
Merck & Co., Inc. 18
Novartis AG 19
Galderma S.A. 20
Paratek Pharmaceuticals, Inc. 21
Helix BioMedix, Inc. 22
Paloma Pharmaceuticals, Inc. 23
Foamix Ltd. 24
Gene Signal International SA. 25
ELORAC, Inc. 26
Cutanea Life Sciences 27
Advancell 28
Rosacea - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
HB -1345 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
omiganan pentahydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
laropiprant - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
aganirsen - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
P -529 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
minocycline - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
sarecycline hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BFH -772 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
carbamide peroxide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brimonidine tartrate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
oxymetazoline hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DLX -1008 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ivermectin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SGT -VD -54 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SIG -990 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ANs -29 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Rosacea Therapeutics - Drug Profile Updates 56
Rosacea Therapeutics - Dormant Products 60
Rosacea - Product Development Milestones 61
Featured News & Press Releases 61
Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 61
Oct 20, 2011: Galderma Announces Positive Phase IIb Results For Investigational Compound Targeting Redness Of Rosacea 61
Aug 15, 2011: Argyle Therapeutics Receives Phase II SBIR Grant To Develop SIG990 62
May 01, 2011: Argyle Presents Preclinical Data On SIG990 At 2011 Society For Information Display Conference 62
Apr 19, 2011: Vicept Announces Positive Results From Second Phase II Study Of V -101 For Treatment Of Type I Rosacea 62
Jan 18, 2011: Foamix Announces Enrollment In Phase II Clinical Trial Of Topical Minocycline Foam For Rosacea 63
Jan 10, 2011: Vicept Reports Positive Phase II Data Of V -101 In Type I Rosacea 63
Nov 18, 2010: Elorac Announces Phase III Study Results Of Carbamide Peroxide For Treatment Of Acne And Rosacea 64
Aug 05, 2010: Vicept Therapeutics Announces Positive Clinical Study Results Of V -101 For The Treatment Of The Erythema Of Rosacea 64
May 31, 2010: Foamix To Present At The UBS 2010 Global Specialty Pharmaceuticals Conference 65

Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67                                                                      

List of Tables

Number of Products Under Development for Rosacea, H1 2013 8
Products under Development for Rosacea - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Discovery and Pre -Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Allergan, Inc., H1 2013 17
Merck & Co., Inc., H1 2013 18
Novartis AG, H1 2013 19
Galderma S.A., H1 2013 20
Paratek Pharmaceuticals, Inc., H1 2013 21
Helix BioMedix, Inc., H1 2013 22
Paloma Pharmaceuticals, Inc., H1 2013 23
Foamix Ltd., H1 2013 24
Gene Signal International SA., H1 2013 25
ELORAC, Inc., H1 2013 26
Cutanea Life Sciences, H1 2013 27
Advancell, H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 33
Rosacea Therapeutics - Drug Profile Updates 56
Rosacea Therapeutics - Dormant Products 60 
List of Figures

Number of Products under Development for Rosacea, H1 2013 8
Products under Development for Rosacea - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Discovery and Pre -Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 29
Assessment by Route of Administration, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Molecule Type, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 33

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing